Versant Capital Management’s Ocular Therapeutix OCUL Stock Holding History
Bought
Maintained
Sold
Other funds holding OCUL
SR
Versant Capital Management's OCUL Position: Q3 2026 in Review
Versant Capital Management increased its Ocular Therapeutix (OCUL) stake by 21% in Q3 2026, buying an estimated $744 and bringing the position to 435 shares worth $3.34K. The position accounts for ﹤0.01% of the portfolio, ranked #2526.
Versant Capital Management first reported a position in OCUL in Q3 2024 and has held it in 9 quarters since. The position peaked at $3.52K in Q2 2026. 263 funds tracked by Wall St. Rank hold OCUL as of Q3 2026.
- Versant Capital Management held 435 shares of Ocular Therapeutix worth $3.34K as of Q3 2026.
- Versant Capital Management bought 76 Ocular Therapeutix shares in Q3 2026, an estimated $744.
- Ocular Therapeutix made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2526 holding.
- Versant Capital Management first reported a position in Ocular Therapeutix in Q3 2024 and has held it in 9 quarters since.
- Versant Capital Management's Ocular Therapeutix position peaked at $3.52K in Q2 2026.
- 263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2026.
Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.